



# Oncological clearance of minimally invasive approaches for clinical N0 non-small cell lung cancer

Since the 1960s, lobectomy with systemic lymph node (LN) dissection has been the standard surgical treatment for patients with stage I or II non-small cell lung cancer (NSCLC). The efficacy of LN dissection for lung cancer depends on the accurate staging and the likelihood of survival benefit. After surgical resection, 10–20% of clinical N0 lung cancer converts to pathologic N1 or N2 disease. Moreover, evaluating the postoperative locoregional recurrences at the dissected area is an important factor to judge the proper approach for lung cancer surgery. Although video-assisted thoracoscopic surgery (VATS) lobectomy for lung cancer is increasingly accepted as a minimally invasive surgery, it is now widely performed with a lack of clear evidence regarding the clearance of the LN dissection. Furthermore, the novel minimally invasive approaches, such as the single-port VATS and the robotic-assisted thoracic surgery, have increased in adaptation for lung cancer surgery in the past decade.

This focused series is directed to the thoracic surgeons who are performing the minimally invasive surgery for early-stage lung cancer. Experts on each minimally invasive approach will comprehensively introduce their techniques and the results of their oncological clearance. Further prospective randomized controlled trials that compare each minimally invasive approach for early-stage lung cancer are needed to evaluate the oncological efficacy of these minimally invasive approaches.

## Acknowledgments

*Funding:* None.

## Footnote

*Provenance and Peer Review:* This article was commissioned by the editorial office, *Video-Assisted Thoracic Surgery* for the series “Oncological clearance of VATS lobectomy for clinical N0 non-small cell lung cancer”. The article did not undergo external peer review.

*Conflicts of Interest:* The author has completed the ICMJE uniform disclosure form (available at <http://dx.doi.org/10.21037/vats-2019-oc-07>). The series “Oncological clearance of VATS lobectomy for clinical N0 non-small cell lung cancer” was commissioned by the editorial office without any funding or sponsorship. Mingyon Mun served as the unpaid Guest Editor of the series. The author has no other conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.



Mingyon Mun

**Mingyon Mun, MD, PhD**

*Department of Thoracic Surgical Oncology, Cancer Institute Hospital, Tokyo, Japan.*

*(Email: mingyon.mun@jcr.or.jp)*

Received: 25 November 2020. Accepted: 12 December 2020; Published: 15 June 2021.

doi: 10.21037/vats-2019-oc-07

**View this article at:** <http://dx.doi.org/10.21037/vats-2019-oc-07>

doi: 10.21037/vats-2019-oc-07

**Cite this article as:** Mun M. Oncological clearance of minimally invasive approaches for clinical N0 non-small cell lung cancer. *Video-assist Thorac Surg* 2021;6:11.